38 Followers on Owler
OverviewCompetitorsFundingNews & Insights

Spero Therapeutics Competitors or Alternatives

Spero Therapeutics's top competitors include Melinta, Tetraphase and Cipla.

Unlock 5 more competitors →

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

  • FUNDING

    REVENUE

  • EMPLOYEES

    FUNDING

  • REVENUE

  • CEO RATING

  • EMPLOYEES

  • FUNDING

  • REVENUE

Spero Therapeutics's company profile

Esther Rajavelu

President & CEO

82/100
150
$463.8M
$47M
  • $463.8M
    $47M
  • 150
    $463.8M
  • $47M
  • 82/100
  • 150
  • $463.8M
  • $47M
View ProfileView
1
Spero Therapeutics's Competitor - Melinta logo

Christine Ann Miller

President & CEO

88/100
250 - 500
$558.3M
$25M - 100M
  • $558.3M
    $25M - 100M
  • 250 - 500
    $558.3M
  • $25M - 100M
  • 88/100
  • 250 - 500
  • $558.3M
  • $25M - 100M
View ProfileView
2
Spero Therapeutics's Competitor - Tetraphase logo

Larry Edwards

CEO

93/100
25 - 100
$172M
$5M - 25M
  • $172M
    $5M - 25M
  • 25 - 100
    $172M
  • $5M - 25M
  • 93/100
  • 25 - 100
  • $172M
  • $5M - 25M
View ProfileView
3
Spero Therapeutics's Competitor - Cipla logo

Achin Gupta

Managing Director & CEO

82/100
30,313
- -
$3.3B
  • - -
    $3.3B
  • 30,313
    - -
  • $3.3B
  • 82/100
  • 30,313
  • - -
  • $3.3B
View ProfileView
4
Spero Therapeutics's Competitor - Adenium Biotech logo

Paul Goldenheim

CEO

73/100
1 - 25
- -
$5M - 25M
  • - -
    $5M - 25M
  • 1 - 25
    - -
  • $5M - 25M
  • 73/100
  • 1 - 25
  • - -
  • $5M - 25M
View ProfileView
5
Spero Therapeutics's Competitor - Achaogen logo

Blake Wise

CEO

77/100
1 - 25
$221.4M
$100K - 5M
  • $221.4M
    $100K - 5M
  • 1 - 25
    $221.4M
  • $100K - 5M
  • 77/100
  • 1 - 25
  • $221.4M
  • $100K - 5M
View ProfileView
Spero Therapeutics' top 8 competitors are Melinta, Tetraphase, Cipla, UTILITY Therapeutics, Adenium Biotech, Achaogen, VIBATIV and Pear. Together they have raised over 1.4B between their estimated 30.7K employees. Spero Therapeutics has 150 employees and is ranked 3rd among it's top 10 competitors. The top 10 competitors average 3,860.

Spero Therapeutics VS Melinta

Melinta is seen as one of Spero Therapeutics's biggest rivals. Melinta was founded in 2000 in Morris County, New Jersey. Like Spero Therapeutics, Melinta also operates in the Pharmaceuticals & Biotechnology sector. Melinta generates $50M more revenue than Spero Therapeutics.

Spero Therapeutics VS Tetraphase

Tetraphase is one of Spero Therapeutics's top competitors. Tetraphase was founded in 2006, and its headquarters is in Waltham, Massachusetts. Like Spero Therapeutics, Tetraphase also operates in the Pharmaceuticals space. Tetraphase has 84 fewer employees than Spero Therapeutics.

Spero Therapeutics VS Cipla

Cipla is one of Spero Therapeutics's top rivals. Cipla was founded in 1935, and is headquartered in Mumbai, Maharashtra. Like Spero Therapeutics, Cipla also works within the Pharmaceuticals sector. Cipla generates $3.3B more revenue vs. Spero Therapeutics.

Looking for similar companies to Spero Therapeutics?

Similar Companies

Pharmaceuticals companies in Cambridge

See 184 companies 
Pharmaceuticals & Biotechnology companies in Cambridge

See 699 companies 
Pharmaceuticals companies in Massachusetts

See 515 companies 
Pharmaceuticals companies in Greater Boston

See 500 companies 
Pharmaceuticals companies with revenue in $25-100M range

See 844 companies 
Companies in Cambridge with revenue in $25-100M range

See 864 companies 
Pharmaceuticals & Biotechnology companies with revenue in $25-100M range

See 1,504 companies 
Pharmaceuticals & Biotechnology companies in Greater Boston

See 1,629 companies 
Pharmaceuticals & Biotechnology companies in Massachusetts

See 1,721 companies 

Advanced Search

PRO

Discover new companies using five search parameters, including sector, location, public/private company status, employee count, and annual revenue.

Discover new companies using five search parameters.

Trending News for Spero Therapeutics and Spero Therapeutics's Competitors

October 15, 2026GlobeNewswire
CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on adva...
October 15, 2026Quartz
Insitro is eligible for up to about $1.46 billion in milestone payments, plus single-digit royalties on global sales...
October 16, 2026Pharmabiz
AstraZeneca announced that it has entered into a new strategic drug discovery collaboration and licensing agreement with insitro, a leading artificial ...
October 16, 2026Contract Pharma
Collaboration targets MASH and cardiomyopathies in a deal worth up to $1.5 billion....
October 15, 2026Benzinga
AstraZeneca pairs with Insitro on a $1.5B AI collaboration to advance drug targets for MASH and heart conditions.read more...
October 16, 2026Ad-hoc-news
Collaboration and session timing AstraZeneca announced an insitro collaboration on October 15, 2026, focused on AI-supported cardiometabolic therapeuti...
October 15, 2026Louisiananewsupdates
(Albany, New York) - October 15, 2026: DelveInsight's "Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast-2036″ report off...

Frequently Asked Questions about Spero Therapeutics

  1. Who are Spero Therapeutics's top competitors?

    Spero Therapeutics's top 3 competitors are Melinta, Tetraphase, Cipla.

  2. Who is similar to Spero Therapeutics?

    Melinta is the most similar to Spero Therapeutics. Tetraphase and Cipla are also similar to Spero Therapeutics.

  1. Are Spero Therapeutics and Melinta competitors?

    Yes, Melinta is one of Spero Therapeutics’s top competitors.